Open AccessJournal Article
Chronic graft-versus-host disease and other late complications of bone marrow transplantation.
Keith M. Sullivan,Edward Agura,Claudio Anasetti,Frederick R. Appelbaum,Christopher C. Badger,Scott I. Bearman,K Erickson,Mary E.D. Flowers,J.A. Hansen,Thomas P. Loughran +9 more
About:
This article is published in Seminars in Hematology.The article was published on 1991-07-01 and is currently open access. It has received 728 citations till now. The article focuses on the topics: Graft-versus-host disease.read more
Citations
More filters
Journal ArticleDOI
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report
Madan Jagasia,Hildegard T. Greinix,Mukta Arora,Kirsten M. Williams,Daniel Wolff,Edward W. Cowen,Jeanne Palmer,Daniel J. Weisdorf,Nathaniel S. Treister,Guang-Shing Cheng,Holly Kerr,Pamela Stratton,Rafael F. Duarte,George B. McDonald,Yoshihiro Inamoto,Afonso Celso Vigorito,Sally Arai,Manuel B. Datiles,David A. Jacobsohn,Theo Heller,Carrie L. Kitko,Sandra A. Mitchell,Paul J. Martin,Howard M. Shulman,Roy S. Wu,Corey Cutler,Georgia B. Vogelsang,Stephanie J. Lee,Steven Z. Pavletic,Mary E.D. Flowers +29 more
TL;DR: The 2014 NIH consensus maintains the framework of the prior consensus with further refinement based on new evidence, and focuses attention on the causes of organ-specific abnormalities to chronic GVHD.
Journal ArticleDOI
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.
Mohamed L. Sorror,Michael B. Maris,Michael B. Maris,Rainer Storb,Rainer Storb,Frédéric Baron,Brenda M. Sandmaier,Brenda M. Sandmaier,David G. Maloney,David G. Maloney,Barry E. Storer,Barry E. Storer +11 more
TL;DR: The new simple index provided valid and reliable scoring of pretransplant comorbidities that predicted nonrelapse mortality and survival and will be useful for clinical trials and patient counseling before HCT.
Journal ArticleDOI
Graft-versus-host disease
TL;DR: The understanding of the risk factors and causes of GHVD, the cellular and cytokine networks implicated in its pathophysiology, and current strategies to prevent and treat the disease are reviewed.
Journal ArticleDOI
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
Leo Luznik,Paul O'Donnell,Paul O'Donnell,Heather J. Symons,Allen R. Chen,M. Susan Leffell,Marianna Zahurak,Ted Gooley,Ted Gooley,S Piantadosi,Michele Kaup,Richard F. Ambinder,Carol Ann Huff,William Matsui,Javier Bolaños-Meade,Ivan Borrello,Jonathan D. Powell,Elizabeth Harrington,Sandy Warnock,Mary E.D. Flowers,Mary E.D. Flowers,Robert A. Brodsky,Brenda M. Sandmaier,Brenda M. Sandmaier,Rainer Storb,Rainer Storb,Richard J. Jones,Ephraim J. Fuchs +27 more
TL;DR: Nonmyeloablative HLA-haploidentical BMT with posttransplantation Cy is associated with acceptable rates of fatal graft failure and severe aGVHD or cGVHD, and there was a trend toward a lower risk of extensive chronic GVHD (cGVHD) among recipients of 2 versus 1 dose of posttrans transplantation Cy.
Journal ArticleDOI
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
Peter A. McSweeney,Peter A. McSweeney,Peter A. McSweeney,Dietger Niederwieser,Dietger Niederwieser,Dietger Niederwieser,Judith A. Shizuru,Judith A. Shizuru,Judith A. Shizuru,Brenda M. Sandmaier,Brenda M. Sandmaier,Brenda M. Sandmaier,Arthur J. Molina,Arthur J. Molina,Arthur J. Molina,David G. Maloney,David G. Maloney,David G. Maloney,Thomas R. Chauncey,Thomas R. Chauncey,Thomas R. Chauncey,Ted Gooley,Ted Gooley,Ted Gooley,U Hegenbart,U Hegenbart,U Hegenbart,Richard A. Nash,Richard A. Nash,Richard A. Nash,Jerald P. Radich,Jerald P. Radich,Jerald P. Radich,John L. Wagner,John L. Wagner,John L. Wagner,Steven Minor,Steven Minor,Steven Minor,Frederick R. Appelbaum,Frederick R. Appelbaum,Frederick R. Appelbaum,William I. Bensinger,William I. Bensinger,William I. Bensinger,Eileen Bryant,Eileen Bryant,Eileen Bryant,Mary E.D. Flowers,Mary E.D. Flowers,Mary E.D. Flowers,George E. Georges,George E. Georges,George E. Georges,F. Carl Grumet,F. Carl Grumet,F. Carl Grumet,Hans-Peter Kiem,Hans-Peter Kiem,Hans-Peter Kiem,Beverly Torok-Storb,Beverly Torok-Storb,Beverly Torok-Storb,Cong Yu,Cong Yu,Cong Yu,Karl G. Blume,Karl G. Blume,Karl G. Blume,Rainer Storb,Rainer Storb,Rainer Storb +71 more
TL;DR: A novel allografting approach, based on the use of postgrafting immunosuppression to control graft rejection and GVHD, has dramatically reduced the acute toxicities of allogRAFTing.